Wilson Sonsini - ECP

Biotech

Our Industry Coverage

Innovative and passionate; that's how we describe our biotech companies. From cutting-edge biopharmaceutical therapies to bioinformatics, we support our clients’ pursuit of excellence. Through their relentless drive to innovate, we work to protect pivotal intellectual property, navigate regulatory environments, and advise on financing strategy.

Industry Highlights

Celebrating our
founders’ successes

BioTech Industry

2000

Illumina Completes IPO Worth $96 Million

Diagnostics & Research

2009

Genentech Acquired by Roche for $46.8 Billion

Pharmaceuticals

2010

Pacific Biosciences Raises $200 Million in IPO

Diagnostics & Research

2014

Xenon Pharmaceuticals Launches IPO

Drug Discovery, Pharmaceuticals

2016

BioCardia Unveils Reverse Merger

Pharmaceuticals

2017

Denali Therapeutics Makes Record BioTech IPO

Drug Discovery

2018

WuXi AppTec Raises $356 Million IPO

Diagnostics & Research

2020

Applied Molecular Transport Closes IPO at $154 Million

Pharmaceuticals

Attorneys

focused
on this
industry

See all ECP attorneys

Martin
Waters

See all ECP attorneys

recent news

we want to share
with you

Wilson Sonsini Advises 6 Dimensions and Its Portfolio Ignis Therapeutics on Ignis’ $180 Million Series A Financing and Strategic Licensing Agreement with SKBP

Wilson Sonsini Advises 6 Dimensions and Its Portfolio Ignis Therapeutics on Ignis’ $180 Million Series A Financing and Strategic Licensing Agreement with SKBP

Client Highlights11/14/21
Wilson Sonsini Advises Cambridge Epigenetix on IP Matters Related to $88 Million Series D
See all news
See all news

other industries

we have covered

Copyright © 2021 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.

We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content. For more information or to opt-out, visit our privacy policy.